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Abstract
Mycophenolic acid (MPA) is an inosine monophosphate dehydrogenase inhibitor used for
glomerulonephritis treatment. The objective of the current study was to develop a population
pharmacokinetic model for MPA and metabolites in glomerulonephritis in order to enable appropriate
design of MPA regimens in these patients with alterations in kidney structure and function.
Thirty-nine patients with glomerulonephritis and receiving mycophenolate mofetil were recruited to
participate in a 24-hour pharmacokinetic (PK) study. Blood was collected at times 0, 0.5, 1.0, 1.5,
2, 3, 4, 6, 8, 12, and 24 hours and urine was collected over the intervals of 0-6, 6-12, and 12-24 hours.
Plasma and urine samples were assayed for MPA and MPAG by high-performance liquid
chromatography (HPLC), and for AcMPAG by liquid chromatography / mass spectrometry (LC/
MS). Population PK analysis and covariate model building were evaluated using Non-linear Mixed
Effect Modeling software (NONMEM, version 6.2.0, ICON Development Solutions, Ellicott City,
MD).
The final model for MPA and it's metabolites consisted of 9 discrete compartments; 1)depot
gastrointestinal, 2)central MPA, 3)peripheral MPA, 4)gallbladder, 5)MPA urine, 6)MPAG central,
7)MPAG urine, 8)AcMPAG central, and 9)AcMPAG urine compartment. The MPA population
mean estimates for apparent non-renal clearance (ClNR/F) and apparent central volume of distribution
were 14.3 L/hr and 21.1 L, respectively. The mean population estimate for apparent renal clearance
(ClR/F) was dependent on estimated creatinine clearances (eClcr); 0.0975 L/hr for eClcr ≤80 mL/
min and 0.157 L/hr for eClcr > 80 mL/min. Covariate analyses identified: eClcr on CLNR,MPA/F
(P<0.001), eClcr (with a cut-off value at 80 ml/min) on CLR,MPA/F (P<0.025), serum albumin on
CLNR,MPA/F (P<0.01), eClcr on CLR,MPAG/F (P<0.001) and eClcr on CLR,AcMPAG/F (P<0.001).
Evaluation of the final model by visual predictive check showed that most of the observed values
were within the 95th percent prediction interval generated from 100 simulations of the final model.
The current population PK model demonstrated eClcr and serum albumin influenced the renal and
nonrenal components of Cl/F, suggesting patients with glomerulonephritis would have highly altered
MPA exposures.
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Introduction
The pharmacokinetics of mycophenolic acid (MPA), the pharmacologically active component
of mycophenolate mofetil (MMF)(, Roche, Nutley, NJ) are well described in transplant
recipients and population pharmacokinetic models are reported. 1-8 After oral intake, MMF is
rapidly and completely absorbed, hydrolyzed into the active MPA, which is 98% bound to
plasma proteins, including albumin. MPA is primarily metabolized by glucuronidation to form
the 7-O-glucuronide conjugate (7-O-MPAG) which then undergoes elimination via the kidneys
or enterohepatic recirculation back to MPA in the gastrointestinal tract. MPA is also
metabolized to form a minor active acyl-glucuronide (AcMPAG). Besides its use in transplant
patients, MPA is used off-label in induction and maintenance regimens for glomerulonephritis,
including systemic lupus erythematosus (SLE) 9-13 and small vessel vasculitis (SVV).
14-16 The knowledge and applicability of MPA pharmacokinetics data from transplant
populations to other kidney diseases are limited This is because, unlike kidney transplant
patients who receive a 3-4 drug immunosuppressive regimen, glomerulonephritis patients
receive only 1-2 immunosuppressive drugs. Hence, glomerulonephritis patients have a smaller
potential for pharmacokinetic drug-drug interactions, may exhibit different pharmacokinetics
from transplant patients, and may require different exposure targets. In addition, results from
noncompartmental pharmacokinetic analyses have suggested altered disposition of MPA in
glomerulonephritis, 17,18 a finding that is not surprising given urinary protein losses, serum
protein reductions, kidney function declines, and inflammation. Compartmental
pharmacokinetic modeling approaches19 and integrated pharmacokinetic models for MPA and
its metabolites are currently lacking in patients with glomerulonephritis.
The aims of the current study was to develop a population pharmacokinetic model for MPA
and its two metabolites [MPA glucuronide (MPAG) and acyl-MPA glucuronide in patients
with glomerulonephritis using plasma and urine data (AcMPAG)] in order to characterize the
disposition of MPA and its metabolites in this population, to determine the contribution of
relevant covariates such as kidney function and structure abnormalities on MPA
pharmacokinetics, and to develop Bayesian estimators which can accurately estimated MPA
interdose AUC in glomerulonephritis patients.
Methods
Patients and Samples
Data were included from two pharmacokinetic studies in patients with glomerulonephritis from
SLE or SVV and receiving MPA as MMF (Cellcept, Roche, New Jersey) for at least 2 weeks
on a stable dose. All patients were recruited and assessed at one study center, both studies were
approved by the institution's Biomedical Institutional Review Board, and patients provided
written informed consent. Details of these studies and results from noncompartmental
pharmacokinetics for MPA and MPAG were previously described. 17,18
Briefly, blood samples were collected at times 0, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours
and urine was collected from 0-6, 6-12, and 12-24 hours after the initial dose. Plasma and urine
samples were assayed for MPA and MPAG by a high-performance liquid chromatography
(HPLC) with ultraviolet detection assay as previously described.20 Plasma and urine standard
curves for MPA were linear over the range of 0.2-200 μg/mL and 1-50 μg/mL, respectively.
Plasma and urine standard curves for MPAG were linear over the range of 1-200 μg/mL and
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5-1500 μg/mL, respectively. The AcMPAG metabolite was assayed in plasma and urine by
liquid chromatography/mass spectrometry (LC/MS) developed in the laboratory. Tuning,
operation, peak integration, and data analysis were performed in negative ion mode using
multiple reaction monitoring (Analyst software v.1.4.1, Applied Biosystems) and
azidothymidine served as the internal standard. Reverse phase separation (gradient elution
using 0.1% acetic acid aqueous phase and 100% acetonitrile organic mobile phase) was
accomplished using a Zorbax RX-C8 150×2.1mm column with a 5 micron particle size (Agilent
Technologies, CA). Analysis required a 10 μL injection, solvent flow of 0.3 mL/min, and total
run time of 15 minutes per injection. Plasma and urine standard curves for AcMPAG were
linear over the range of 0.01-50 μg/mL and 1-500 μg/mL, respectively. MPAG and AcMPAG
concentrations were represented in terms of MPA-equivalents by multiplying the MPAG and
AcMPAG concentration by 0.646 (molecular mass of MPA to MPAG/AcMPAG) and reported
in mcg/mL. The amount of MPA available from a dose of the prodrug (MMF) was estimated
as 72% of the dose (molecular mass of MPA to MMF).
Population Pharmacokinetic Analysis
Pharmacokinetics of MPA, MPAG, and AcMPAG were evaluated using Non-linear Mixed
Effect Modeling software (NONMEM Version 6.2.0, ICON Development Solutions, Ellicott
City, MD). Initial visual inspection of semi-logarithmic plasma concentration-time plots for
MPA, MPAG and AcMPAG demonstrated bi-exponential and mono-exponential decay
patterns (Figure 1), consistent with a two-compartmental pharmacokinetic model for MPA and
one-compartment pharmacokinetic models for MPAG and AcMPAG. Pharmacokinetic
models were parameterized in terms of apparent clearances and volumes with the subroutines
ADVAN6 TRANS1 and incorporated a gallbladder compartment to account for enterohepatic
recycling of MPA via MPAG. The enterohepatic recycling process was modeled by introducing
a rate constant describing the transfer from the MPAG central compartment to a gallbladder
compartment. During gallbladder emptying, MPAG was transferred and converted back to the
parent MPA in the depot compartment. Double precision and first-order conditional estimation
(FOCE) were used. Inclusion of urine data allowed estimation of apparent renal clearance
(CLR/F) and apparent nonrenal clearance (CLNR/F). Both MPAG and AcMPAG
pharmacokinetics were modeled as a central metabolite compartment for plasma that was
connected to the central MPA compartment. Each metabolite compartment had a non-
reversible elimination pathway to a urine compartment, and an additional elimination pathway
such as through enterohepatic recycling through the gallbladder compartment for MPAG.
Intersubject variability in structural model parameters was estimated by an exponential error
model (Equation 1).
(1)
Where Pj is the individual value for P in the jth individual, θ is the population mean value of
the pharmacokinetic parameter P (e.g. CL/F, Vc/F, etc), and ηj is a random error term (the
difference between the typical value and individual value).
Residual variability εij,k (k=1, 2, 3, 4, 5, 6), which is the discrepancy between the individual
observed (Cobs, ij) ith plasma or urine concentration measured in the jth individual for the MPA,
MPAG, and AcMPAG and the respective individual model-predicted plasma or urine
concentrations (Cpred, ij) in the natural logarithm domain and was modeled according to an
additive error model (Equations 2-7).
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Random effect parameters η and ε were assumed to be symmetrically distributed with 0 mean
and variances of ω2 and σ2, respectively. Different pharmacokinetic models were tested and
the best structural model was chosen based on goodness-of-fit criteria including diagnostic
plots, minimum objective function value (MOFV) after accounting for the number of fitted
parameters, akaike information criteria (AIC), equal to MOFV plus two times the number of
parameters, precision, and physiological plausibility of parameter estimates.
Covariate Models
Covariate models were created to evaluate for the influence of patient demographics (age,
weight, gender), clinical status (serum creatinine, eClcr, serum albumin, urinary protein to
creatinine ratio), and genotypes for single nucleotide polymorphisms relevant for MPA
metabolism or transport (uridine glucuronosyltransferase genes; UGTs, e.g. UGT2B7 C802T,
UGT1A7 T622C, multidrug resistance gene; MDR1, e.g. MDR1 C3435T, and MDR1
C1236T) on the pharmacokinetic parameters. These data were abstracted from the medical
record or research database, where applicable. Kidney function was assessed by estimated
creatinine clearance (eClcr) calculated by the Cockroft-Gault equation. 21
For continuous covariates (age, weight, serum creatinine, eClcr, serum albumin, urinary protein
to creatinine ratio) on the population parameter, Ppop, Equation 8 was used:
(8)
where θp is the typical value of Ppop for a patient with the median covariate value in the
population, COVmedian and θcov is the change in ln(Ppop) per unit change in ln(COV/
COVmedian). For some continuous covariates which influenced Ppop only below a critical cutoff
value, the covariate model was modified as shown in Equations 9 and 10:
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where θp1 is the typical value of Ppop for a patient with COVmedian below or equal to the cutoff
value, θcov is the estimated effect of the covariate on Ppop below or equal to the cutoff value,
and θp2 is the typical value of Ppop for a patient with a COV value above the cutoff value. The
critical cutoff values were determined graphically from the plots of the posthoc
pharmacokinetic parameter estimates versus covariates.
For categorical covariates (race, gender, genotypes) on Ppop was modeled according to
Equations 11 and 12:
(11)
(12)
where θp is the typical value of Ppop (e.g. CL/F, Vc/F, etc) for reference COV, θcove is the
estimated fractional change in θp for the investigated covariate. Likelihood ratio tests to
compare hierarchical models were performed by comparing differences in MVOF between
models to χ2 distributions with degrees of freedom equal to the difference in the number of
parameters A reduction in MVOF of >3.84 (1 degree of freedom) from the base or previous
model to the current model was designated as statistically significant at p<0.05.
The incorporation of covariates in the final model was determined by stepwise forward addition
followed by backward elimination. During forward addition, covariates at the p < 0.05 level
were included in the model, and during backward elimination, covariates at the p < 0.01 level
were retained in the model.
Model Validation
A visual predictive check was employed to evaluate the predictability of the model. One
hundred data sets were simulated each for plasma and urine MPA, MPAG, and AcMPAG from
the final model. The observed data were superimposed with the 2.5th, 50th, and 97.5th
percentiles of the simulated data calculated at each time point. Binomial exact tests were
performed to evaluate the percentage of observed concentrations that were out of the 95th%
prediction intervals.
Bayesian estimation of inter-dose area-under-curve (AUC0-12)
Using the observed data and final model parameters, a combination of three plasma samples
(from 0 to 6 hr postdose) and one urine sample (0-6 hr postdose collection) were used to
estimate MPA AUC0–12 of the glomerulonephritis patients included in the analysis. Due to the
limited number of patients in the study, data-splitting or circular permutation method was used
to validate the Bayesian estimators. The full dataset was randomly divided into five groups,
each containing 20% of the patients. Five different subsets of four groups containing 80% of
the data were obtained. The population parameters estimated in the five “80% subsets” were
used as priors to calculate the individual pharmacokinetic parameters of the patients in the
Sam and Joy Page 5













remaining subset using Bayesian estimation. Predicted MPA AUC0–12 were compared with
the observed values and the predictive performance was evaluated by calculating mean relative
prediction error (%MPE) as a measure of bias and root mean squared relative prediction error
(%RMSE) as a measure of precision. 22 Observed MPA AUC0–12 were determined by the
linear trapezoidal method/
Results
The characteristics from the combined set of 39 lupus nephritis and ANCA-associated
vasculitis patients are presented in Table 1. The patients were predominantly Caucasian (60%)
and African-American (28%) race. A minimal to moderate level of kidney dysfunction was
present; eClcr 91.3±45.7 mL/min and urinary protein to creatinine ratio 0.8±1.6, with
conserved serum albumin (4.2±0.5 g/dL). Approximately 40% of patients were receiving
double immunosuppressant therapy with glucocorticoids (31%) or cyclosporine (8%).
A full steady-state 12-hour plasma concentration vs time profile was generated for all 39
patients. The entire dataset produced a total of 444 MPA, 441 MPAG, and 363 AcMPAG
plasma and a total of 130 MPA, 130 MPAG, and 71 AcMPAG urine concentrations. Figure 1
shows the observed steady state plasma concentration vs time profiles for MPA, MPAG, and
AcMPAG after orally administered MMF and demonstrate secondary peaks between 4 and 12
hours consistent with enterohepatic recycling of MPA.
Introduction of enterohepatic recycling of MPAG in pharmacokinetic model decreased the AIC
by 647 units relative to the model without enterohepatic recycling. Introduction of
interconversion of AcMPAG back to MPA via the central compartment in the pharmacokinetic
model decreased the AIC by 110 units relative to the model without this interconversion. While
several patient plasma concentration time curves demonstrated an absorption lag time of MPA,
its inclusion into models resulted in a reduction of the MVOF but with the cost of decreased
precision of other data parameters and was therefore not incorporated. Duration of gallbladder
emptying was fixed at 0.01 hours. 4,8 Due to insufficient data collected around the secondary
peak, the transfer rate constant of MPAG from the gallbladder to the depot compartments
(k41) was fixed at 67.5 hr−1 8. The final model parameters are presented in Table 2. Figure 2
is a schematic representation of the final model employing plasma and urine concentration data
for MPA, MPAG, and AcMPAG.
The covariates were examined to determine their relationship with eta values for apparent Clr/
F, apparent Clnr/F, and the central compartment volume (Vc/F). Stepwise forward addition
identified the following significant covariate effects: eClcr on CLNR,MPA/F (ΔMVOF=−19.6,
P<0.001), eClcr (with a cut-off value at 80 ml/min/1.73m2) on CLR,MPA/F (ΔMVOF=−8.8,
P<0.025), serum albumin on CLNR,MPA/F (ΔMOF=−6.6, P<0.01), eClcr on CLR,MPAG/F
(ΔMVOF=−18.7, P<0.001) and eClcr on CLR,AcMPAG/F (ΔMVOF=−11.0, P<0.001). All these
covariates remained significant (p<0.01) during backward elimination.
Table 2 shows the population parameter estimates and covariate relationships for MPA,
MPAG, and AcMPAG for the final model. In general, parameters were estimated with
acceptable precision (7-53% relative standard error, %RSE). eClcr ≤80 mL/min had a covariate
effect on ClR,MPA/F (Equation 13).
(13)
For apparent CLNR/F, eClcr had a positive effect, while serum albumin was found to have an
inverse effect (Equation 14).
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For MPAG and AcMPAG, increased eClcr resulted in increased apparent CLR/F for each
respective metabolite. (Equations 15 and 16).
(15)
(16)
None of the UGT2B7, UGT1A7, and MDR1 genotypes were found to be significant in the final
model.
Model diagnostic plots for plasma MPA, MPAG and AcMPAG data are shown in Figures 3,
4 and 5, respectively. Similar to the plasma data, the natural-logarithm transformed population
predicted concentrations (ln(PRED)) and individual predicted concentrations (ln(IPRED)) for
the urine MPA, MPAG and AcMPAG data (not shown) were in good general agreement with
the natural-logarithm transformed observed concentrations (ln(DV)). Similar to the plasma
data, no trends were associated with the weighted residuals (WRES) when plotted against
increasing values of ln(PRED) and time after dose for the urine MPA, MPAG and AcMPAG
data (not shown). These plots showed that our comprehensive model adequately described the
data.
The results of the visual predictive check evaluation for plasma and urine MPA, MPAG, and
AcMPAG are presented in Figures 6 and 7, respectively. Results of binomial tests showed that
4.28% (95% C.I. 2.60-6.60%) of observed plasma MPA concentrations, 4.31% (95% C.I.
2.61-6.65%) of observed plasma MPAG concentrations and 3.86% (95% C.I. 2.12-6.39%) of
observed plasma AcMPAG concentrations were out of the 95th% prediction intervals. Results
of binomial tests showed that 1.54% (95% C.I. 0.187-5.45%) of observed urine MPA
concentrations, 2.31% (95% C.I. 0.478-6.60%) of observed urine MPAG concentrations and
5.63% (95% C.I. 1.56-13.8%) of observed urine AcMPAG concentrations were out of the
95th% prediction intervals. Overall, the percentages of observations that were out of the
95th% prediction intervals were not statistically different from 5% as indicated by their 95%
C.I. This analysis suggests that the final model provided an adequate fit to the data.
Figure 8 demonstrates the relationships of predicted population values for MPA CL/F, CLR/
F, CLNR/F and area-under-curve in a dosing interval (AUC0-tau) after a 1000 mg MMF dose
in a glomerulonephritis population exhibiting selected values for eClcr and serum albumin that
are clinically relevant.
For the analysis of Bayesian estimation of inter-dose AUC0-12, Table 3 shows the time-points
with unbiased predictions of MPA AUC0–12 with measured MPA AUC0–12 as indicated by
the %MPE. A %MPE not significantly different from zero was indicative of unbiased
predictions. The predictions had %RMSE of less than 35%, indicating reasonable imprecision
of the estimations.
Discussion
The current study reported a population pharmacokinetic analysis of MPA and its metabolites
MPAG and AcMPAG, in a group of patients with glomerulonephritis secondary to SVV and
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SLE. This study was necessary to investigate the influence of patient-level characteristics
including kidney function (e.g. eClcr), kidney structure (urinary protein to creatinine ratio),
and serum protein (serum albumin concentration) that are altered in glomerulonephritis on
MPA pharmacokinetics. Additionally, demographic and genotype variables were investigated
for their influence on MPA pharmacokinetics. The population approach enabled us to estimate
mean pharmacokinetic parameters, inter-individual variability, and residual variability, as well
as to evaluate for covariate effects on MPA pharmacokinetics. As opposed to kidney transplant
recipients, little is known about pharmacokinetic variability of MPA in glomerulonephritis,
despite being used off-label for this indication for almost a decade.
As compared to our previous study in kidney transplant patients, our glomerulonephritis
population had higher population mean (%RSE) absorption rate constant (Ka) [1.16 hr−1
(15.2%) vs 0.67 hr−1 (24.8%)], higher apparent intercompartmental clearance (Q/F) [23.4 L/
hr (16.4%) vs 8.11 L/hr (24.2%)], and lower VC/F. [21.1 L (34.1%) vs 25.9 L (34.9%)]. 1
However different dosage forms of MPA were used in each of these studies, which may have
accounted for variability in Ka. Published MPA population models by others in the kidney
transplant population have reported population mean Ka estimates that range from 2.27 hr−1
to 4.1 hr−1 5,7,23, which are also greater than the estimate in glomerulonephritis. Mean
population estimates for VC/F have ranged from 10.3 to 97.7 L 4,5,7,24, a range encompassing
the mean value found in the current study. 1 A strength of the current study was the collection
of urine samples, which enabled estimation of the ClR/F component of apparent oral clearance
(CL/F). The model resulted in two population mean ClR/F estimates for MPA based on eClcr
levels of ≤80 mL/min and >80 mL/min. The ClR/F estimate was nearly 2-fold higher in patients
with eClcr values of >80 mL/min (0.157 L/hr) versus ≤80 mL/min (0.0975 L/hr). Apparent
renal clearance estimates of MPAG and AcMPAG were an order of magnitude greater than
MPA estimates.
As would be expected, the ClNR/F estimate (%RSE) for MPA was significantly greater [14.3
L/hr (8.04%)] than the ClR/F estimates [0.0975 L/hr (20.8%) and 0.157 L/hr (20.5%)] as MPA
is primarily metabolized by the liver. These estimates were not available from previously
published MPA pharmacokinetic models as urine concentrations were not measured. Previous
studies have reported only ranges for MPA CL/F between 11.9 L/hr and 33 L/hr. 4,5,7,24 A
recent publication in 38 patients with glomerulonephritis receiving MMF reported higher mean
(%RSE) VC/F [52.4 L (17%)], higher Ka [6.2 hr−1 (22%)], lower VP/F [262 L (5%)], and lower
Q/F [16.2 L/hr (22%)] than our current study. 19 However, the studies were comprised of
different types of patients, with our study having a higher percentage of females, more diverse
racial make-up, higher kidney function (eClcr), and a lower percentage of patients on
concomitant glucocorticoids. The final structural model that fit the MPA pharmacokinetic data
obtained from our glomerulonephritis patients consisted of nine compartments, a model
slightly more complex than our previous model in kidney transplant recipients 1, and higher
complexity than the previous glomerulonephritis model. 19
Although the volumes of the central metabolite compartments are not uniquely identifiable in
this analysis, if we use the central MPAG compartment apparent volume of 4.4 L from a
previous study, 8 the percentage of MPAG clearance that undergo recycling through the
gallbladder in glomerulonephritis patients would be estimated as 17.9%. Previous reports of
the percentage of MPA clearance that underwent recycling through gallbladder were 29.1%
and 37%, respectively, in the two reported studies. 8, 19 The current model shows that
AcMPAG undergoes rapid reversible interconversion with the parent MPA in plasma. This is
consistent with recent animal data from our laboratory which suggests that AcMPAG is actually
cleaved to MPA by nonspecific esterases within the liver (data not shown), whereas MPAG is
reportedly cleaved by β-glucuronidases in the intestine. 25
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It is known that there is a large degree of interpatient variability in the pharmacokinetic
parameters of MPA in kidney transplant patients. 26 Previous studies have reported CL/F
interpatient variability in the range of 28% to 41% 5,6, and VC/F interpatient variability in the
range of 18% to 87.8%. 1,3 In the current study, estimated interpatient variability for MPA
pharmacokinetic parameters (%RSE) were: CLR,MPA/F [72.5% (30.9%)], CLNR,MPA/F
[39.7% (19.1%)], and Vc/F [143% (50.7%)]. This variability and relationships between
exposure and treatment-related outcomes in transplant patients supports the development of
therapeutic drug monitoring strategies for MPA. 26-33
Covariate modeling enabled the evaluation of disease-state variables on estimates of MPA
renal and nonrenal clearance, and apparent oral clearance, for the purpose of simulating the
influence of typical clinical alterations in albumin and kidney function (eClcr) found in patients
with glomerulonephritis on clearance parameters and ultimately MPA exposures. Covariate
modeling demonstrated that MPA ClR/F is directly related to eClcr (covariate coefficient 1.33)
in patients with eClcr values of ≤80 mL/min and MPA ClNR/F is directly related to eClcr
(covariate coefficient 0.831). A glomerulonephritis patient with eClcr of 60 mL/min would be
predicted to have an approximately 3-fold higher MPA ClR/F than a patient with an eClcr of
30 mL/min (0.11 L/hr vs 0.04 L/hr). Serum albumin concentrations were also found to influence
ClNR/F, with decreased serum albumin resulting in increased ClNR/F (covariate coefficient
−1.35). An increase in eClcr from 30 to 60 mL/min in the presence of a normal serum albumin
(4.4 g/dL) would double the calculated ClNR/F from 5.5 to 9.7 L/hr. For the same increase in
eClcr, patients with reduced serum albumin to 2.5 g/dL would have a doubling of the calculated
CLNR/F, above that demonstrated at each level of eClcr in patients with normal serum albumin
concentrations (from 11.7 to 21 L/hr). The clinical manifestations of glomerulonephritis are
typically not solely a reduction in serum albumin or a reduction in eClcr, but some combination
of these previous covariates. Hence, the influence of the combination of factors needs to be
considered for their effects on MPA exposure. For a group of patients with normal serum
albumin concentrations, the AUC 0-tau would be decreased when evaluating patients with
increased eClcr values 30 to 120 mL/min (131 to 41.4 mg hr/L). When these same patients
also have serum albumin values reduced from 4.4 to 2.5 g/dL, the AUC 0-tau is reduced another
2-fold at each level of eClcr (from 61.2 to 19.4 mg hr/L). While it is important to note that
MPA AUC 0-tau clinical targets are not defined for glomerulonephritis, if one were to target
the AUC 0-tau values suggested for renal transplant recipients (30 to 60 mg hr/L) as a starting
point for therapy, the covariate effects would result in many patients either above or below the
former targets. In particular, patients with low serum albumin and patients with low eClcr
would be at highest risk. As unbound MPA AUC 0-tau may be more relevant to target in patients
with these clinical manifestations, future assessments should address these unbound targets.
However, the relative contribution of unbound levels to efficacy versus availability for
elimination would dictate the relevance of unbound levels.
The ClR/F of MPA's metabolites (MPAG and AcMPAG) were also found to positively
influence kidney function, e.g. creatinine clearance. Glomerulonephritis patients with
decreased eClcr would be expected to have at least transiently increased metabolite (AcMPAG
and MPAG) concentrations prior to recycling and subsequently, at least transiently increased
MPA concentrations. However, the relative influence of decreased eClcr on levels of MPA or
its metabolites may be influenced by altered metabolism secondary to reductions in protein
binding of MPA to serum albumin due to uremic competitors, 5 or concomitant cyclosporine
therapy. 19 Decreased kidney function will lead to reduced renal clearance of MPAG and
increased biliary excretion. As a result, more MPAG will undergo enterohepatic recirculation
and conversion back to MPA. Our kidney disease model, e.g. glomerulonephritis, would be
predicted to result in reductions in protein binding of MPA secondary to reductions in serum
albumin due to kidney losses and also due to accumulation of metabolites (MPAG and
AcMPAG) secondary to the loss of kidney function. Since we measured MPA and metabolites
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in the urine, the ClR/F component could be estimated and the ClNR/F component could also
be calculated. Our results suggest that the ClNR/F component of MPA Cl/F is influenced to a
greater extent than ClR/F in patients with glomerulonephritis. Studies into the influences of the
systemic diseases that result in glomerulonephritis on phase II drug metabolizing processes
may elucidate the role of serum albumin versus alterations in UGTs on nonrenal clearance.
Finally, our data demonstrate a clear application of the model using a combination of three
time points that accurately estimate the MPA exposure. Based on the final population
pharmacokinetic model, accurate prediction of MAP AUC0–12 is feasible using bayesian
estimation at nine different combinations of three time-points as shown in Table 3. This would
facilitate the optimization of the exposure of MPA in glomerulonephritis patients.
Conclusions
This study reported a population pharmacokinetic model for MPA and its glucuronide
metabolites in patients with glomerulonephritis secondary to SLE and SVV. Unlike previous
models of MPA pharmacokinetics, our model was developed with extensive plasma and urine
sample collections from a well-defined population of patients and allowed the estimation of
both the renal and nonrenal components of apparent oral clearance. The resulting parameter
estimates were considerably different than those obtained in many of the previous publications
of kidney transplant patients receiving MPA. Two covariates, eClcr and serum albumin,
influenced the renal and nonrenal components of apparent clearance. The clinical relevance of
the current study can be realized when using the population parameters to simulate
AUC 0-tau values under scenarios of altered creatinine clearance and/or altered serum albumin.
We demonstrated that patients with glomerulonephritis would have highly altered MPA
exposures when one includes assessment of covariates on renal and nonrenal apparent
clearance estimates. Additionally, our model can be applied clinically as demonstrated by the
combination of three time points accurately estimating MPA exposure. Future work will
elucidate unbound exposures and relevance to efficacy, toxicity, and metabolic pathways.
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Observed Plasma Concentration Versus Time After Dose. Figure shows observed plasma
concentration versus time after dose for a). mycophenolic acid (MPA), b). mycophenolic acid
glucuronide (MPAG), and c). acyl-mycophenolic acid glucuronide (AcMPAG).
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Final compartment model for mycophenolic acid (MPA), mycophenolic acid glucuronide
(MPAG), and acylmycophenolic acid glucuronide (AcMPAG) plasma and urine data.
Abbreviations: mycophenolic acid, MPA; mycophenolic acid glucuronide, MPAG; acyl-
mycophenolic acid glucuronide, AcMPAG; absorption rate constant, ka; apparent renal
clearance of MPA, CLR, MPA/F; apparent non-renal clearance of MPA, CLNR, MPA/F;
compartment, CMT; apparent volume of central compartment, VC/F; apparent volume of
peripheral compartment, VP/F; apparent renal clearance of MPAG, CLR, MPAG/F; apparent
renal clearance of AcMPAG, CLR, AcMPAG/F; ratio of fraction of MPA metabolized to MPAG
to volume of distribution of MPAG, FM1*; ratio of fraction of MPA metabolized to AcMPAG
to volume of distribution of AcMPAG, FM2*; rate constant for the transfer of MPAG from
central to gall bladder compartment, k84; rate constant for the transfer of AcMPAG from central
to MPA central compartment, k102; rate constant for the transfer of MPAG from gallbladder
to depot; k41.
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Mycophenolic Acid in Plasma Goodness-of-Fit Plots. (Upper left and right panels) Natural
logarithmic-transformed population and individual predicted plasma mycophenolic acid
(MPA) concentration vs natural logarithmic-transformed observed plasma MPA concentration.
(Lower left and right panels) Natural logarithmic-transformed population predicted plasma
MPA concentration and time after dose vs weighted residuals (WRES).
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Mycophenolic Acid Glucuronide in Plasma Goodness-of-Fit Plots. (Upper left and right
panels) Natural logarithmic-transformed population and individual predicted plasma
mycophenolic acid glucuronide (MPAG) concentration vs natural logarithmic-transformed
observed plasma MPAG concentration. (Lower left and right panels) Natural logarithmic-
transformed population predicted plasma MPAG concentration and time after dose vs weighted
residuals (WRES).
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Acyl-Mycophenolic Acid Glucuronide in Plasma Goodness-of-Fit Plots. (Upper left and right
panels) Natural logarithmic-transformed population and individual predicted plasma
mycophenolic acid acyl glucuronide (AcMPAG) concentration vs natural logarithmic-
transformed observed plasma AcMPAG concentration. (Lower left and right panels) Natural
logarithmic-transformed population predicted plasma AcMPAG concentration and time after
dose vs weighted residuals (WRES).
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Visual predictive check for plasma A) MPA, B) MPAG and C) AcMPAG. Observed data (●)
compared to the 97.5th (upper dotted line), 50th (middle solid line) and 2.5th (lower dotted line)
percentiles of the simulated (100) data sets.
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Visual predictive check for urine A) MPA, B) MPAG and C) AcMPAG. Observed data (●)
compared to the 97.5th (upper dotted line), 50th (middle solid line) and 2.5th (lower dotted line)
percentiles of the simulated (100) data sets.
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Three-dimensional surface plots showing the relationships between A) population predicted
CLNR/F of MPA, eCRCL and ALB; B) population predicted CLR/F of MPA, eCRCL and ALB;
C) population predicted CL/F (sum of CLNR/F and CLR/F) of MPA, eCRCL and ALB; D)
AUC0-tau, eCRCL and ALB, in glomerulonephritis patients.
Sam and Joy Page 20

























Sam and Joy Page 21
Table 1
Study Patient Characteristics (n=39)
Mean ± standard deviation Range (min-max)
Age (years) 46.9±14.8 24-78
Weight (kg) 85.7±20.9 47.4-128
Gender (male/female) 11/28
Race n (%)
 Caucasian 23 (59)
 African-American 11 (28)
 American-Indian 2 (5)
 Asian 2 (5)
 Other 1 (3)
Serum albumin (g/dL) 4.2±0.5 2.9-5.2
Serum creatinine (mg/dL) 1.3±0.7 0.6-3.4
Estimated Creatinine Clearance (mL/min)a 91.3±45.7 25.1-239
Urinary protein to creatinine ratio 0.8±1.6 0-7.90
Concomitant glucocorticoids (%) 12 (31)
Concomitant cyclosporine (%) 3 (8)
Mycophenolate mofetil dose (mg) 827±325 250-1500
a
– estimated by Cockroft and Gault equation 21
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Table 2
Final parameter estimates of the population modeling





 ka (hr−1) 1.16(15.2)
 CLR, MPA/F [eCLCR ≤ 80 mL/min] (L/hr) 0.0975 (20.8) 72.5 (30.9)
 CLR, MPA/F [eCLCR > 80 mL/min] (L/hr) 0.157(20.5) 72.5 (30.9)
 CLNR, MPA/F (L/hr) 14.3(8.04) 39.7(19.1)
 VC/F (L) 21.1 (34.1) 143 (50.7)
 VP/F (L) 1240(23.4)
 Q/F (L/hr) 23.4 (16.4)
Covariate coefficient
 Effect of creatinine clearance on CLR, MPA/F [eCLCR ≤ 80 mL/min], eCRCL_ CLR, MPA/F a 1.33(33.2)
 Effect of creatinine clearance on CLNR, MPA/F, eCRCL_ CLnR, MPA/Fb 0.831 (18.5)
 Effect of albumin on CLNR, MPA/F, ALB_ CLNR, MPA/F b −1.35(31.5)
Residual error estimates (standard deviation)
 MPA, plasma (μg/mL) 1.81 (18.7)
 MPA, urine (μg/mL) 2.49 (16.6)
Mycophenolic Acid Glucuronide (MPAG)
Fixed effects
 CLR, MPAG/F (L/hr) 1.77(12.7) 71.8(25.4)
 FM1* 0.271 (14.9) 72.7 (37.7)
 k84(hr−1) 0.0878 (53.2)
Covariate coefficient
 Effect of creatinine clearance on CLR, MPAG/F, eCRCL_ CLR, MPAG/F c 0.641 (37.0)
Residual error estimates (standard deviation)
 MPAG, plasma (μg/mL) 1.50(7.54)
 MPAG, urine (μg/mL) 1.77(14.0)
Acyl-mycophenolic acid glucuronide (AcMPAG)
Fixed effects
 CLR, AcMPAG/F (L/hr) 1.75(18.2) 95.9 (29.5)
 FM2* 0.0142 (24.4) 80.4 (25.9)
 k102 (hr−1) 1.63 (40.3)
Covariate coefficient
 Effect of creatinine clearance on CLR, AcMPAG/F, eCRCL_ CLR, AcMPAG/F d 1.00 (31.4)
Residual error estimates (standard deviation)
 AcMPAG, plasma (μg/mL) 1.54 (7.83)
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Model parameter (units) Estimate (%RSE) Interindividual
variability, CV%
(%RSE)
 AcMPAG, urine (μg/mL) 1.31 (24.6)
Abbreviations: coefficient of variation, CV; estimated creatinine clearance, eClcr; percent relative standard error, % RSE; absorption rate constant,
ka; apparent renal clearance of MPA, CLR, MPA/F; apparent non-renal clearance of MPA, CLNR, MPA/F; apparent volume of central compartment,
VC/F; apparent volume of peripheral compartment, VP/F; apparent renal clearance of MPAG, CLR, MPAG/F; apparent renal clearance of AcMPAG,
CLR, AcMPAG/F; ratio of fraction of MPA metabolized to MPAG to volume of distribution of MPAG, FM1*; ratio of fraction of MPA metabolized
to AcMPAG to volume of distribution of AcMPAG, FM2*; rate constant for the transfer of MPAG from central to gall bladder compartment, k84;
rate constant for the transfer of AcMPAG from central to MPA central compartment, k102;
a
CLR, MPA/F individual = CLR, MPA/F [(eCRCL/54.93)CRCL_CLR,MPA]×EXP(η CLR, MPA/F);
b
CLNR, MPA/F individual = CLNR, MPA/F [(eCRCL/88.54)CRCL_CLNR,MPA]× [(ALB/4.2)ALB_CLNR,MPA]×EXP(η CLnr, MPA/F);
c
CLR, MPAG/F individual = CLR, MPAG/F [(eCLCR/88.54)CLCR_CLR,MPAG]×EXP(η CLR, MPAG/F);
d
CLR, AcMPAG/F individual = CLR, AcMPAG/F [(eCLCR/88.54)CLCR_CLR,AcMPAG]×EXP(η CLR, AcMPAG/F)
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Table 3
Predictive performance of the Bayesian estimators of MPA inter-dose area-under-curve (AUC0-12)
Time (hr) % MPE (95% CI) % RMSE
0, 1, 3 −8.26 (−18.1, 1.60) 31.7
0, 1, 4 −8.11 (−18.0, 1.83) 31.9
0, 2, 4 −7.41 (−18.0, 3.15) 33.6
0, 2, 3 −7.81 (−18.3, 2.71) 33.6
0, 3, 4 −5.77 (−16.7, 5.13) 34.3
0, 3, 6 −7.76 (−18.3, 2.74) 33.6
0, 1.5, 4 −7.53 (−18.3, 3.21) 33.6
0, 1.5, 6 −8.95 (−19.5, 1.58) 33.9
0, 4, 6 −7.93 (−18.4, 2.58) 33.6
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